BLISS GVS PHARMA LTD. - 506197 - Outcome Of Board Meeting Held On June 16, 2020
We would like to inform you that Board Meeting of the Company was held today i.e. on Tuesday, June 16, 2020 at registered office of the Company. In pursuant to Regulation 30 and 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved as attached. BLISS GVS PHARMA LTD. - 506197 - Intimation Of Request Letters Received For Re-Classification/Removal Of Shareholding From "Promoter And Promoter Group Category' To "Public Category' As Per Regulation 31A Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
The Company is in receipt of requests under Regulation 31A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 from the following Promoters and Members of Promoter Group of the Company:- 1) Gautam Rasiklal Ashra 2) Arjun Gautam Ashra 3) Antara Gautam Ashra 4) Mamta Gautam Ashra 5) Gautam Rasiklal Ashra on behalf of Arjun & Antara Trust 6) Vijayaben Kanji Ashra 7) Kanji Forex Private Limited 8) Kanji Pitamber Forex Private Limited 9) Genteel Trading Company Private Limited 10) Mangesh Ghanashyam Wagle 11) Mangesh Ghanashyam Wagle HUF BLISS GVS PHARMA LTD. - 506197 - Board Meeting Intimation for Board Meeting Intimation For Notice Of The Board Meeting To Consider Audited Standalone And Consolidated Financial Results For The Quarter And Year Ended March 31, 2020 And Recommendation Of Dividend, If Any
BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/06/2020 ,inter alia, to consider and approve the Audited Standalone and Consolidated Financial Statements and Results of the Company for the quarter and financial year ended March 31, 2020; and recommend a dividend, if any, for the financial year ended March 31, 2020. BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Resignation of Director
Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Para A of part A of schedule III to the said regulation, we hereby inform you that the Company has received a letter from Mr. Gautam Ashra (DIN: 00140942) wherein he has resigned from the post of Non-Executive Director of the Company with effect from June 12, 2020. Further, enclosed herewith information as required under 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD /4/2015 dated September 09, 2015, as an Annexure. You are requested to take above information on record. BLISS GVS PHARMA LTD. - 506197 - Certificate Under Regulation 40(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended March 31, 2020
Please find enclosed herewith the half yearly compliance certificate issued by Company Secretary in Practice as per Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended March 31, 2020. Kindly take the same on record. BLISS GVS PHARMA LTD. - 506197 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed herewith a certificate received from Universal Capital Securities Private Limited, Registrar and Share Transfer Agent of the Company under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2020. Kindly take the same on record. BLISS GVS PHARMA LTD. - 506197 - Statement Of Investor Complaints For The Quarter Ended March 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 1230 Name of the Signatory :- Aditi BhattDesignation :- Company Secretary and Compliance Officer BLISS GVS PHARMA LTD. - 506197 - Compliance Certificate - Regulation 7(3) Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended March 31, 2020
Please find enclosed herewith certificate under Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended March 31, 2020 Kindly take the same on record. BLISS GVS PHARMA LTD. - 506197 - Shareholding for the Period Ended March 31, 2020
Bliss GVS Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click here BLISS GVS PHARMA LTD. - 506197 - Closure of Trading Window
This is to inform you that pursuant to Securities Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force) and in accordance with the Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons, the Trading window for dealing in securities/shares of Bliss GVS Pharma Limited ('the Company') will remain closed for all the Designated Persons and their immediate relatives of the Company with effect from Wednesday, April 01, 2020 until 48 hours after the announcement of the audited financial results of the Company for the quarter and year ended March 31, 2020. The Board meeting for declaration of Audited Financial Results for the quarter and year ended March 31, 2020 shall be intimated later.